79 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals, Inc.
13 Jan 25
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
7:01am
and in the Europe Union and in Great Britian for the treatment of PK deficiency in adult patients. It is under investigation for pediatric PK deficiency … Subtypes of Thalassemia PYRUKYND® is under investigation for thalassemia and is not approved anywhere for that use. Sources: Taher AT. ENERGIZE
8-K
EX-99.2
vrdsqxyfi98mbxq15k
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am